JPRN-UMIN000009636已完成未知
Study of the clinical utility and safety in combination use of the GLP-1 analogue and BG in type 2 diabetic patients - Study of the clinical utility and safety in combination use of the GLP-1 analogue and BG in type 2 diabetic patients
Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine0 个研究点目标入组 60 人开始时间: 2012年12月26日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)severe ketosis, diabetic coma within 6 months 2)severe infection, before operation, severe trauma 3)severe hepatic dysfunction 4)or severe renal dysfunction (eGFR: more than 1.5mg/dl) 5)Patients who use of insulin 6)pregnacy 7)Allergy for sitagliptin, nateglinide,liraglutide and exenatide 8)Patients judged by the investigator to be ineligible for some other reason
研究者
相似试验
已完成
不适用
Study of the clinical utility and safety in combination use of the GLI-1 analogue and Insulin degludec in type 2 diabetic patients.JPRN-UMIN000016966Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine30
招募中
不适用
A clinical study on safety and efficacy of combined intraarterial cisplatin and 5-fluorouracil with systemic pegylated interferon alfa-2b for advanced hepatocellular carcinomahepatocellular carcinomaJPRN-UMIN000009107Iwate Medical University60
已完成
4 期
A clinical evaluation of safety of combination therapy with Rapid Onset Opioid and Short Acting Opioid.Cancer PainJPRN-UMIN000019224Kansai Electric Power Hospital30
已完成
不适用
Study on effect and safety for combination of immune checkpoint inhibitor and molecular-targeted therapies for liver cancerunresectable hepatocellular carcinomaJPRN-UMIN000043639agoya University Hospital91
已完成
不适用
Investigation on efficacy and safety of combination treatment with imidafenacin and mirabegron in patients with overactive bladder.overactive bladderJPRN-UMIN000016236Clinical Research Support Center Kyushu30